Lv5
1230 积分 2024-08-01 加入
Sunitinib malate in solitary fibrous tumor (SFT)
16天前
已完结
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
25天前
已完结
Neoadjuvant therapy in renal cell carcinoma with tumor thrombus: A systematic review and meta-analysis
1个月前
已完结
Sorafenib and radioiodine-refractory differentiated thyroid cancer (RR-DTC): a systematic review and meta-analysis
5个月前
已完结
Sorafenib: a review of its use in patients with radioactive iodine-refractory, metastatic differentiated thyroid carcinoma
5个月前
已完结
Role of cellular, molecular and tumor microenvironment in hepatocellular carcinoma: Possible targets and future directions in the regorafenib era
5个月前
已完结
Current and Future Research Into the Mechanism of Action of Regorafenib
5个月前
已关闭
Imatinib mesylate as first-line therapy in patients with chronic myeloid leukemia in accelerated phase and blast phase: A retrospective analysis
6个月前
已完结
Nilotinib vs. Dasatinib in Achieving MR4.5 for de novo Chronic Myeloid Leukemia: the Randomized JALSG CML212 Study
7个月前
已关闭
Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective Study
7个月前
已完结
皖公网安备34019202002308
